Anti srpk2

Manufactured by BD

Sourced in United States

Anti-SRPK2 is a laboratory tool used for detecting and quantifying the SRPK2 protein. It is a specific antibody that can be used in various analytical techniques, such as Western blotting, immunohistochemistry, and ELISA, to identify and measure the presence of SRPK2 in biological samples.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using anti srpk2

Antibody Validation for Epigenetic Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies were purchased from the following companies: anti‐H3K27me1, anti‐H3K27me3, anti‐H3K79me1, anti‐H3K79me2, anti‐histone H3, anti‐hnRNP I, anti‐KDM4A, anti‐KDM5A, anti‐KDM5C, anti‐snRNP70, anti‐tubulin, and anti‐U2AF2 from Abcam (Cambridge, MA, USA); anti‐hnRNP A2/B1 from Acris (San Diego, CA, USA); anti‐SR protein‐specific kinases (SRPK)1 and anti‐SRPK2 from BD Biosciences (San Diego, CA, USA); anti‐AKT, anti‐H3K27me2, anti‐protein phosphatase‐1 (PP1), anti‐phospho‐PP1 at Thr320, anti‐phospho‐AKT at Ser473, and anti‐cleaved‐CASPASE‐3 from Cell Signaling Technology (Billerica, MA, USA); anti‐H3K4me1, anti‐H3K4me2, anti‐H3K4me3, and anti‐H3K36me3 from Millipore; anti‐pro‐CASPASE‐3 and anti‐KDM7A from GeneTex (SanAntonio, TX, USA); anti‐hnRNP C1/C2, anti‐BAX, and anti‐BCL2L1 from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti‐hnRNP A1 from Sigma; and anti‐SRSF1 and anti‐SRSF3 from Zymed (San Francisco, CA, USA).

Lee C., Chang W., Chang Y., Yang J., Chang C., Hsu K., Chen Y., Liu T., Chen Y., Lin S., Wu Y, & Chang J. (2019). Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5‐diamino‐6‐chloro‐N‐(N‐(2,6‐dichlorobenzoyl)carbamimidoyl)pyrazine‐2‐carboxide. Molecular Oncology, 13(8), 1744-1762.

+ Open protocol

+ Expand

Western Blot Analysis of Gastric Cancer Cell Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Whole cell extracts of gastric cancer cells were prepared using modified RIPA lysis buffer (Merck Millipore, Billerica, MA) containing protease inhibitors (Roche, Indianapolis, IN) and phosphatase inhibitors (Thermo Scientific, Bremen, Germany). 30 μg of protein from each condition was used for western blot. Proteins were resolved on acrylamide gel and hybridized on nitrocellulose membrane which were probed with primary antibodies, and developed using Luminol reagent (Santa Cruz Biotechnology, Dallas, TX). Anti-CLK1 (catalog# 209681) and anti-SRSF2 (catalog# 204916) primary antibodies were obtained from Abcam (Cambridge, MA). Anti-Phospho-AKT (S473) (catalog# 4058) and anti-AKT (catalog# 9272) antibodies were obtained from Cell Signaling Technologies, Beverly, MA). Anti-phospho-SRPK2 (catalog# 71817; Millipore, Burlington, MA), anti-SRPK2 (catalog# 611118; BD Biosciences, San Jose, CA). β-Actin antibody (catalog# A5316; Sigma, St. Louis, MO) was used a loading control. ImageJ software was used to obtain densitometry of the resultant bands [24] .

Babu N., Pinto S.M., Biswas M., Subbannayya T., Rajappa M., Mohan S.V., Advani J., Rajagopalan P., Sathe G., Syed N., Radhakrishna V.D., Muthusamy O., Navani S., Kumar R.V., Gopisetty G., Rajkumar T., Radhakrishnan P., Thiyagarajan S., Pandey A., Gowda H., Majumder P, & Chatterjee A. (2020). Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 23(5).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!